InSightec Completes Additional Financing Round of $30.9 Million, Taps New CEO
12/10/2012 6:44:19 AM
More...
|
InSightec's ExAblate Neuro System Awarded European CE Mark for Non-invasive Treatment of Neurological Disorders in the Brain
12/4/2012 7:24:27 AM
More...
|
InSightec Wins FDA Approval for Bone Tumor Ultrasound Therapy
10/22/2012 7:19:13 AM
More...
|
InSightec Receives FDA Approval to Begin Phase I Parkinson's Trial
8/20/2012 10:50:06 AM
More...
|
GE Healthcare Dumps $27.5 Million Into InSightec
5/29/2012 8:24:51 AM
More...
|
GE Healthcare Invests $13.8 Million in InSightec
2/27/2012 7:40:32 AM
More...
|
InSightec Release: Enrollment in First MRgFUS Essential Tremor Feasibility Trial Completed
1/3/2012 9:47:44 AM
More...
|
InSightec Release: NICE Issues Updated Guidance for MR Guided Focused Ultrasound for Uterine Fibroids
11/28/2011 11:25:57 AM
More...
|
InSightec Release: ExAblate(R) Neuro has Been Used to treat 30 Patients with Chronic Neurological Disorders Such as Essential Tremor, Neuropathic Pain and Parkinson's Disease
9/21/2011 10:09:23 AM
More...
|
InSightec Release: 23 Patients With Organ Confined Low Risk Prostate Cancer Have Been Treated in Clinical Trials Using the ExAblate(R) Non-Invasive Prostate Cancer System
7/13/2011 10:18:32 AM
More...
|
|